Fourth-generation accommodating IOL gets FDA ok

Article

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market. The newest generation of the Crystalens provides an increased depth of focus without creating any additional dysphotopsia, thereby enhancing the near vision and maintaining the intermediate and distance vision improvement offered by the third-generation lens.

John Hovanesian, MD, FACS of the Jules Stein Eye Institute, UCLA, California, US and colleagues implanted the lens, using the same surgical protocol as with previous versions of the Crystalens, into eyes (n=125) with visually significant cataract combined with astigmatism of

Bausch & Lomb has now begun shipping of the fourth-generation Crystalens HD.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.